Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR7.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR8.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR1.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR5.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR4.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR2.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR9.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR6.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR3.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR14.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR12.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR10.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR13.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR11.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q/A
(Amendment No. 1)
 
(Mark One)
 
x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2011
 
OR
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from               to            
 
COMMISSION FILE NUMBER 333-142076
 
IRIS BIOTECHNOLOGIES INC.
(Exact Name of small business issuer as specified in its charter)
 
California
 
77-0506396
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
 
5201 Great America Parkway, Suite 320, Santa Clara, California 95054
(Address of principal executive offices) (Zip Code)
 
Issuer’s telephone Number: (408) 867-2885
 
Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o   No x
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer o
 
Accelerated filer  o
     
Non-accelerated filer o
 
Smaller reporting company  x
(Do not check if a smaller
reporting company)
   
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No x
 
As of August 12, 2011 the issuer had 12,184,751 outstanding shares of Common Stock.
 

 
1

 
 
EXPLANATORY NOTE


Iris BioTechnologies, Inc. is filing this Amendment No. 1 (the “Amendment No. 1”) to its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011, which was originally filed on August 15, 2011 (the “Original Filing”) for the sole purpose of furnishing Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). As required by Rule 405(a)(2)(ii) of Regulation S-T, Exhibit 101 was required to be furnished by amendment within 30 days of the original filing.
 
No other changes have been made to the Original Filing. This Amendment No.1 does not reflect events that may have occurred subsequent to the Original Filing date, and does not modify or update in any way disclosures made in the Form 10-Q for the fiscal quarter ended June 30, 2011.
 
Pursuant to Rule 406T of Regulation S-T, the interactive data files contained in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
 
 
 
 
 
 
 
2

 
 
 
 
ITEM 6. EXHIBITS.
 
Exhibit
Number
 
Description of Exhibit
     
31.1*
 
Certifications required by Rule 13a-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*
 
Certification of Chief Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C.§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS**
 
XBRL Instance Document
     
101.SCH**
 
XBRL Taxonomy Extension Schema Document
     
101.CAL**
 
XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF**
 
XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB**
 
XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE**
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
* These exhibits were previously filed with our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, filed with the Securities and Exchange Commission on August 15, 2011.
 
**XBRL  (eXtensbile Business Reporting Language) interactive data files are furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under those sections.
 
 
 
3

 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
IRIS BIOTECHNOLOGIES INC.
 
       
 September 15, 2011
By:
/s/ Simon Chin
 
   
Simon Chin
 
   
President, Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Accounting Officer and Principal Financial Officer)
 
       



 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
4